Danaher Corp
DHRQ3 2023(DHR Q2 FY2023)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$690.5M
AI Revenue (Q)
$59.1M
Total Revenue (Q)
$5.9B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q2 FY2023 (three-month period ended June 30, 2023). Total sales $7,157M (including E&AS). Segments: Biotechnology $1,885M, Life Sciences $1,796M, Diagnostics $2,231M, Environmental & Applied Solutions $1,245M. No AI revenue disclosure. No mention of AI in filing narrative. Conservative 1% estimate for embedded instrument algorithms. Math: ~$72M estimated / $7,157M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $7,157 [three-month period ended June 30, 2023]
10-Q Q2 FY2023, Consolidated Condensed Statements of Earnings
Biotechnology $1,885; Life Sciences $1,796; Diagnostics $2,231; Environmental & Applied Solutions $1,245 [three-month period ended June 30, 2023]
10-Q Q2 FY2023, Note 5 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instrumentsEnvironmental & Applied Solutions
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix